Literature DB >> 6609999

The postantibiotic effect in the treatment of experimental meningitis caused by Streptococcus pneumoniae in rabbits.

M G Täuber, O Zak, W M Scheld, B Hengstler, M A Sande.   

Abstract

The relevance of a postantibiotic effect in the treatment of pneumococcal meningitis was evaluated in a rabbit model. After administration of a single intravenous bolus of ampicillin at various dosages, such an effect was observed in all animals. The duration of this effect in vivo (2.5-18 hr) was consistently longer than that in vitro (1-4.3 hr); however, in rabbits the postantibiotic effect was eliminated by the administration of intravenous plus intracisternal beta-lactamase. In an assessment of the potential therapeutic benefit of the postantibiotic effect, the efficacy to two regimens of treatment with different intervals between doses was compared. One group of animals received ampicillin every 4 hr and another every 12 hr. With sufficiently high doses, drug concentrations in cerebrospinal fluid exceeded the minimal bactericidal concentration for most of the 4-hr interval but for only about one-third of the 12-hr interval. The rate of cure was similar for the two regimens and approximated 100% when peak drug concentrations in cerebrospinal fluid exceeded the minimal bactericidal concentration by at least 10-fold.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6609999     DOI: 10.1093/infdis/149.4.575

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  Streptococcus pneumoniae: Activity of Newer Agents Against Penicillin-Resistant Strains.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

Review 2.  Continuous infusion of beta-lactam antibiotics.

Authors:  W A Craig; S C Ebert
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

3.  Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks.

Authors:  Anouk E Muller; Joost DeJongh; Ymka Bult; Wil H F Goessens; Johan W Mouton; Meindert Danhof; John N van den Anker
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

4.  Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model.

Authors:  E Löwdin; I Odenholt; S Bengtsson; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

5.  Variation in postantibiotic effect of clindamycin against clinical isolates of Staphylococcus aureus and implications for dosing of patients with osteomyelitis.

Authors:  I B Xue; P G Davey; G Phillips
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

6.  Classic reaction kinetics can explain complex patterns of antibiotic action.

Authors:  Pia Abel Zur Wiesch; Sören Abel; Spyridon Gkotzis; Paolo Ocampo; Jan Engelstädter; Trevor Hinkley; Carsten Magnus; Matthew K Waldor; Klas Udekwu; Ted Cohen
Journal:  Sci Transl Med       Date:  2015-05-13       Impact factor: 17.956

7.  Pharmacokinetics of florfenicol in cerebrospinal fluid and plasma of calves.

Authors:  B A de Craene; P Deprez; E D'Haese; H J Nelis; W Van den Bossche; P De Leenheer
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

8.  Postantibiotic effects of imipenem, norfloxacin, and amikacin in vitro and in vivo.

Authors:  J Renneberg; M Walder
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

9.  Newly made enzymes determine ongoing cell wall synthesis and the antibacterial effects of cell wall synthesis inhibitors.

Authors:  E Tuomanen
Journal:  J Bacteriol       Date:  1986-08       Impact factor: 3.490

10.  Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.

Authors:  I R Friedland; M Paris; S Ehrett; S Hickey; K Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.